Vaxcyte, Inc. PCVX R2K
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -81.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PCVX Vaxcyte, Inc. R2K | 51.40 | - | $7.42B | - | -33.02% | -30.55% | - | -81.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 180.79M | 226.22M | 242.38M | 274.28M | 345.85M |
| Operating Income | -13.94M | -12.23M | -12.14M | -15.84M | -27.60M | -21.22M | -21.31M | -19.45M | -23.14M | -23.73M | -26.95M | -39.22M | -47.89M | -58.58M | -71.19M | -87.15M | -113.03M | -114.47M | -152.98M | - | - | -180.79M | -226.22M | -242.38M | -274.28M | -345.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -175.92M | -221.23M | -237.18M | -264.48M | -340.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -140.72M | -166.57M | -212.83M | -246.51M | -320.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -13.67M | -10.66M | -11.32M | -14.62M | -27.14M | -20.32M | -21.02M | -20.74M | -21.22M | -23.68M | -26.61M | -38.99M | -48.53M | -57.92M | -60.46M | -68.34M | -92.66M | -95.02M | -128.70M | - | - | -140.72M | -166.57M | -212.83M | -246.51M | -320.62M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.46 | -0.51 | -0.68 | -0.80 | -0.93 | -0.70 | -0.70 | -0.91 | -0.85 | -1.10 | -0.83 | - | -1.04 | -1.22 | -1.56 | - | -2.30 |
| R&D Expense | 12.63M | 9.97M | 9.63M | 13.38M | 24.32M | 18.18M | 16.41M | 14.66M | 17.26M | 17.65M | 20.43M | 31.68M | 38.47M | 47.68M | 58.08M | 72.69M | 97.42M | 94.59M | 131.51M | 116.94M | - | 148.13M | 194.18M | 209.93M | - | 312.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 209.26M | 393.04M | 569.55M | 923.67M |
| Operating Income | -35.53M | -54.15M | -89.58M | - | -209.26M | -393.04M | -569.55M | -923.67M |
| EBITDA | - | - | - | - | -214.03M | -382.87M | -553.70M | -898.82M |
| Interest Expense | - | - | - | 7.00K | 2.00K | 0 | 0 | - |
| Pretax Income | - | - | - | - | -223.49M | -402.27M | -463.93M | -766.63M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -29.48M | -50.27M | -89.22M | - | -223.49M | -402.27M | -463.93M | -766.63M |
| Diluted EPS | - | - | -3.02 | - | -3.44 | -4.14 | -3.80 | -5.63 |
| R&D Expense | 30.14M | 45.61M | 73.56M | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -81.01% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +58.20% |
| 6 Months: | +2.31% |
| 3 Months: | -16.75% |
| 1 Month: | -10.33% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 65.70M | 392.83M | - | 1.01B | 1.41B | 3.51B | 3.00B |
| Current Assets | - | - | - | - | - | 942.55M | 1.10B | 1.79B | 1.63B |
| Cash & Equivalents | - | - | 58.98M | 386.20M | - | 834.66M | 397.45M | 387.88M | 173.96M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 11.76M | 46.98M | - | 52.56M | 167.45M | 205.50M | 317.21M |
| Current Liabilities | - | - | 11.05M | 46.86M | - | 40.52M | 145.34M | 140.18M | 205.75M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 17.94M | 29.22M | 71.11M | 117.48M |
| Total Equity | -29.13M | -57.73M | -106.37M | 345.84M | - | 953.61M | 1.24B | 3.31B | 2.69B |
| Shares Outstanding | - | - | - | - | - | 79.47M | 95.36M | 124.89M | 131.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.47M | -47.15M | -46.63M | - | -170.60M | -296.79M | -452.63M | -655.58M |
| Investing Cash Flow | -1.77M | -1.20M | -1.10M | - | 74.58M | -773.31M | -2.01B | 437.35M |
| Financing Cash Flow | 62.19M | 41.57M | 374.87M | - | 861.55M | 639.81M | 2.45B | 2.01M |
| Capital Expenditure | -1.77M | -1.20M | -1.16M | - | -5.84M | -67.88M | -119.16M | -56.97M |
| Free Cash Flow | -32.24M | -48.34M | -47.78M | - | -176.44M | -364.67M | -571.79M | -712.55M |
| Net Change in Cash | - | - | - | - | 765.53M | -430.29M | -9.79M | -216.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 51.1% | 47.3% | -25.8% | - | -23.4% | -32.4% | -14.0% | -28.5% |
| ROCE % | - | -99.1% | -25.9% | - | -21.7% | -31.1% | -16.9% | -33.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 11.48% | 16.58M | $852.00M |
| 2 | FMR, LLC | 11.42% | 16.49M | $847.73M |
| 3 | T. Rowe Price Investment Management, Inc. | 8.40% | 12.13M | $623.28M |
| 4 | RA Capital Management, L.P. | 7.95% | 11.47M | $589.79M |
| 5 | Blackrock Inc. | 7.60% | 10.97M | $563.95M |
| 6 | Vanguard Portfolio Management LLC | 4.35% | 6.28M | $322.77M |
| 7 | Vanguard Capital Management LLC | 4.34% | 6.27M | $322.11M |
| 8 | Wellington Management Group, LLP | 3.89% | 5.61M | $288.59M |
| 9 | Paradigm Biocapital Advisors LP | 3.32% | 4.79M | $246.36M |
| 10 | State Street Corporation | 3.08% | 4.44M | $228.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PCVX